Evidence map›Paper›PMID 38764767›Full record

ArticleWorld journal of gastroenterology2024

FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.

Jing-Ya Yin, Tian-Yuan Yang, Bing-Qing Yang, Chen-Xue Hou, Jun-Nan Li, Yue Li, Qi Wang

Abstract readComparative Study
In one paragraph

Article in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing-Ya YinCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Tian-Yuan YangCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Bing-Qing YangCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Chen-Xue HouDepartment of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Jun-Nan LiBeijing institute of infectious disease, Beijing 100015, China.
Yue LiDepartment of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Qi WangCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) with hepatic histological NAFLD activity score ≥ 4 and fibrosis stage F ≥ 2 is regarded as "at risk" non-alcoholic steatohepatitis (NASH). Based on an international consensus, NAFLD and NASH were renamed as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), respectively; hence, we introduced the term "high-risk MASH". Diagnostic values of seven non-invasive models, including FibroScan-aspartate transaminase (FAST), fibrosis-4 (FIB-4), aspartate transaminase to platelet ratio index (APRI),

aimTo assess the clinical value of seven non-invasive models as alternatives to liver biopsy for diagnosing high-risk MASH.

methodsA retrospective analysis was conducted on 309 patients diagnosed with NAFLD

resultsMASLD diagnostic criteria were met by 99.4% patients with NAFLD. The MASLD population was analyzed in two cohorts: Overall population (279 patients) and the subgroup (117 patients) who underwent liver transient elastography (FibroScan). In the overall population, FIB-4 showed better diagnostic efficacy and higher PPV, with sensitivity, specificity, PPV, NPV, and AUROC of 26.9%, 95.2%, 73.5%, 72.2%, and 0.75. APRI, Forns index, and aspartate transaminase to alanine transaminase ratio (ARR) showed moderate diagnostic efficacy, whereas S index and gamma-glutamyl transpeptidase to platelet ratio (GPR) were relatively weaker. In the subgroup, FAST had the highest diagnostic efficacy, its sensitivity, specificity, PPV, NPV, and AUROC were 44.2%, 92.3%, 82.1%, 67.4%, and 0.82. The FIB-4 AUROC was 0.76. S index and GPR exhibited almost no diagnostic value for high-risk MASH.

conclusionFAST and FIB-4 could replace liver biopsy as more effectively diagnostic methods for high-risk MASH compared to APRI, Forns index, ARR, S index, and GPR; FAST is superior to FIB-4.

Indexed as

Aspartate AminotransferasesElasticity Imaging TechniquesLiverNon-alcoholic Fatty Liver DiseasePredictive Value of TestsAdultAgedBiomarkersBiopsyFemaleHumansMaleMiddle AgedPlatelet CountRetrospective StudiesRisk AssessmentAspartate AminotransferasesBiomarkersDiagnostic valueHigh-risk metabolic dysfunction-associated steatohepatitisLiver biopsyMetabolic dysfunction-associated steatotic liver diseaseNon-invasive models

Identifiers

PMID38764767
PMCPMC11099389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.